Mangalam Drugs and Organics Ltd Financials
Company Logo

Mangalam Drugs and Organics Ltd Financial Statement

Mangalam Drugs and Organics Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue57.35
Operating Expense61.85
Net Profit-13.73
Net Profit Margin-23.94
Earning Per Share-8.67
EBIDTA-5.31
Effective Tax RateTBA

Mangalam Drugs and Organics Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual318.23
Operating Expenses Annual282.43
Operating Profit Annual36.30
Interest Annual14.93
Depreciation16.38
Net Profit Annual6.92
Tax Annual-1.93

Mangalam Drugs and Organics Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning1
Cash Flow from Operations42.76
Cash Flow from Investing-19.47
Cash Flow from Financing-21.71
Cash Flow at the End2.57

Mangalam Drugs and Organics Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)11.41
PBIT Margin (%)6.26
PBT Margin (%)5.84
Net PROFIT Margin (%)2.17
Return On Networth / Equity (%)4.76
Return On Networth /Employed (%)7.94
Return On Assets (%)2.76
Total Debt / Equity (X)0.70
Asset Turnover Ratio (%)1.27

Mangalam Drugs and Organics Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual158.21
Total Current Assets Annual198.99
Non Current Assets Annual160.25
Total Shareholders Funds Annual148.66
Total Assets Annual359.24

Mangalam Drugs and Organics Ltd Earning Calls

EPS (INR)

Expected

0.00

Reported

-8.72

Surprise

0.00%

Mar 2025

EPS beaten by 0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

FAQS on Mangalam Drugs and Organics Ltd Financials

As of Oct 3, 2025, Mangalam Drugs and Organics Ltd has a market capitalization of 117.48 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Mangalam Drugs and Organics Ltd is not with a debt-to-equity ratio of 0.60.

In FY 2024 , Mangalam Drugs and Organics Ltd recorded a total revenue of approximately 317.58 Cr marking a significant milestone in the company's financial performance.

Mangalam Drugs and Organics Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and -0.1% annually, respectively..

Mangalam Drugs and Organics Ltd's current PE ratio is 16.98.

Mangalam Drugs and Organics Ltd's ROCE averaged 5.3% from the FY ending March 2023 to 2025, with a median of 6.4%. It peaked at 8.2% in March 2025, reflecting strong capital efficiency over the period..

Mangalam Drugs and Organics Ltd's latest EBIT is Rs. 19.92 Cr, surpassing the average EBIT of Rs. 12.65 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions